(ACRS) Aclaris Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00461U1051

ACRS: Cancer, Dermatitis, Autoimmune, Inflammatory, Disease

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases. Headquartered in Wayne, Pennsylvania, the company operates through two primary segments: Therapeutics and Contract Research. The Therapeutics segment concentrates on identifying and advancing therapeutic solutions for significant unmet medical needs in immuno-inflammatory diseases. The Contract Research segment provides specialized laboratory services, supporting external clients in their research endeavors.

The companys pipeline includes several promising drug candidates. Zunsemetinib (ATI-450), a novel MK2 inhibitor, is currently in Phase 1b/2 clinical trials for the treatment of metastatic breast and pancreatic cancer. ATI-1777, a soft JAK 1/3 inhibitor, has completed Phase 2b trials for moderate to severe atopic dermatitis and other dermatological conditions, showcasing potential in addressing inflammatory skin diseases. Additionally, ATI-2138, an oral covalent inhibitor targeting ITK and JAK3, is under Phase 1 evaluation for T cell-mediated autoimmune diseases, highlighting Aclaris commitment to innovative immunomodulatory therapies.

Founded in 2012, Aclaris Therapeutics has established itself as a dedicated player in the biopharmaceutical industry, with a strong emphasis on scientific rigor and patient-centric innovation. For more information, visit their website at https://www.aclaristx.com.

Three-Month Forecast: Based on the provided and , Aclaris Therapeutics stock (NASDAQ:ACRS) is expected to face headwinds in the near term. Technically, the stock is trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 0.16 suggests low volatility, but the stocks last price of $1.96 is below the 20-day SMA of $2.25, signaling potential downside pressure. Fundamentally, the companys negative return on equity (ROE) of -28.44% and a forward P/E ratio of 0.00 raise concerns about profitability and valuation. The price-to-sales (P/S) ratio of 7.71 is elevated, which may indicate a rich valuation relative to its revenue generation. Overall, the stock may experience selling pressure in the next three months, driven by technical weakness and fundamental concerns.

Additional Sources for ACRS Stock

ACRS Stock Overview

Market Cap in USD 198m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2015-10-07

ACRS Stock Ratings

Growth 5y 22.1%
Fundamental -50.4%
Dividend 0.0%
Rel. Strength Industry 34.5
Analysts 4.14/5
Fair Price Momentum 1.33 USD
Fair Price DCF -

ACRS Dividends

No Dividends Paid

ACRS Growth Ratios

Growth Correlation 3m -93.1%
Growth Correlation 12m 67.2%
Growth Correlation 5y -38.2%
CAGR 5y 12.24%
CAGR/Max DD 5y 0.13
Sharpe Ratio 12m -0.04
Alpha 16.93
Beta 2.24
Volatility 72.20%
Current Volume 945.6k
Average Volume 20d 629.5k
What is the price of ACRS stocks?
As of March 15, 2025, the stock is trading at USD 1.56 with a total of 945,560 shares traded.
Over the past week, the price has changed by -14.75%, over one month by -33.05%, over three months by -48.34% and over the past year by +35.65%.
Is Aclaris Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Aclaris Therapeutics (NASDAQ:ACRS) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -50.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACRS as of March 2025 is 1.33. This means that ACRS is currently overvalued and has a potential downside of -14.74%.
Is ACRS a buy, sell or hold?
Aclaris Therapeutics has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy ACRS.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ACRS stock price target?
According to ValueRays Forecast Model, ACRS Aclaris Therapeutics will be worth about 1.6 in March 2026. The stock is currently trading at 1.56. This means that the stock has a potential downside of -0.64%.
Issuer Forecast Upside
Wallstreet Target Price 9.8 530.1%
Analysts Target Price 10 541%
ValueRay Target Price 1.6 -0.6%